



September 24, 2021

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2017-003998-34/ Novartis Protocol ID CEGF816A2302

A Randomized, Open-label, Phase III Study of single agent Nazartinib Versus Investigator's choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients with locally advanced or metastatic Non-Small Cell Lung Cancer harboring EGFR Activating Mutations

Trial CEGF816A2302 was cancelled with no patient enrollment and as such, no results will be reported.